Serum proteome profiling of primary breast cancer indicates a specific biomarker profile

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1051-1056

  Böhm, Daniel ^a   Keller, Ksenia ^a   Wehrwein, Nelli ^a   Lebrecht, Antje ^a   Schmidt, Marcus ^a   Kol̈bl, Heinz ^a   Grus, Franz Hermann ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Biomarker discovery; Breast cancer; MALDI TOF TOF; Proteome profiling; SELDI TOF; Serum

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; INTRADUCTAL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053168221     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1420     Document Type: Article

References (30)

1. Jensen AR, Madsen AH and Overgaard J: Trends in breast cancer during three decades in Denmark: stage at diagnosis, surgical management and survival. Acta Oncol 47: 537-544, 2008.
2. Muller-Schimpfle MP, Heindel W, Kettritz U, Schulz-Wendtland R and Bick U: [Consensus Meeting of Course Directors in Breast Imaging, 9 May 2009, in Frankfurt am Main - Topic: Masses]. Rofo 182: 671-675, 2010 (In German).
3. Schmidt M, Victor A, Bratzel D, et al: Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer - comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 20: 258-264, 2009.
4. Rosenberg RD, Lando JF, Hunt WC, et al: The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993. Cancer 78: 1731-1739, 1996. (Pubitemid 26330901)
5. Ugnat AM, Xie L, Morriss J, Semenciw R and Mao Y: Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer 90: 1138-1143, 2004. (Pubitemid 38496804)
6. Sant M, Allemani C, Capocaccia R, et al: Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 106: 416-422, 2003. (Pubitemid 36870406)
7. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312, 2007. (Pubitemid 350232263)
8. Desmetz C, Bascoul-Mollevi C, Rochaix P, et al: Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 15: 4733-4741, 2009.
9. Liotta LA, Ferrari M and Petricoin E: Clinical proteomics: written in blood. Nature 425: 905, 2003.
10. Liotta LA and Petricoin EF: Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116: 26-30, 2006. (Pubitemid 43121786)
11. Ebert MP, Korc M, Malfertheiner P and Rocken C: Advances, challenges, and limitations in serum-proteome-based cancer diagnosis. J Proteome Res 5: 19-25, 2006. (Pubitemid 43100793)
12. Kiehntopf M, Siegmund R and Deufel T: Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med 45: 1435-1449, 2007. (Pubitemid 350036581)
13. Li J, Zhao J, Yu X, et al: Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 11: 8312-8320, 2005. (Pubitemid 41746942)
14. Pawlik TM and Kuerer HM: The evolving role of proteomics in the early detection of breast cancer. Int J Fertil Womens Med 50: 212-216, 2005. (Pubitemid 46638703)
15. Mathelin C, Cromer A, Wendling C, Tomasetto C and Rio M-C: Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 96: 83-90, 2006.
16. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002. (Pubitemid 34809839)
17. Belluco C, Petricoin EF, Mammano E, et al: Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 14: 2470-2476, 2007. (Pubitemid 47389555)
18. Van Winden AWJ, Van den Broek I, Gast M-CW, et al: Serum degradome markers for the detection of breast cancer. J Proteome Res 9: 3781-3788, 2010.
19. Pietrowska M, Marczak L, Polanska J, et al: Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer. J Transl Med 7: 60, 2009.
20. Zhang GQ, Du J and Pang D: [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry]. Zhonghua Zhong Liu Za Zhi 28: 204-207, 2006 (In Chinese).
21. Van de Vijver M, He Y, Van't Veer L, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002. (Pubitemid 35461656)
22. Schmidt M, Hasenclever D, Schaeffer M, et al: Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14: 5849-5855, 2008.
23. Ginestier C, Charafe-Jauffret E, Bertucci F, et al: Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 161: 1223-1233, 2002.
24. Elmore JG, Armstrong K, Lehman CD and Fletcher SW: Screening for breast cancer. JAMA 293: 1245-1256, 2005. (Pubitemid 40327910)
25. Song J, Patel M, Rosenzweig CN, et al: Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52: 1045-1053, 2006. (Pubitemid 43794416)
26. Peng J, Stanley AJ, Cairns D, Selby PJ and Banks RE: Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles - initial evaluation using low molecular weight serum peaks. Proteomics 9: 492-498, 2009.
27. Villanueva J, Shaffer DR, Philip J, et al: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284, 2006. (Pubitemid 43121812)
28. Fan Y, Shi L, Liu Q, et al: Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer 8: 79, 2009.
29. Ward DG, Suggett N, Cheng Y, et al: Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94: 1898-1905, 2006. (Pubitemid 43882582)
30. Yang SY, Xiao XY, Zhang WG, et al: Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5: 83, 2005.